Therefore, to fill this gap of knowledge, this study aims to investigate the effectiveness and safety of two CDK4/6 inhibitors, palbociclib and ribociclib, for real-world breast cancer patients’ data from the clinical practice in the state of Qatar. This evidence concerns the gene CDK4 and breast cancer.